Kanaph Therapeutics Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
30
- Stock Symbol
-
0082N0
- Share Price
-
$6.67
- (As of Friday Closing)
Kanaph Therapeutics General Information
Description
Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
Contact Information
Website
www.kanaphtx.comCorporate Office
- 5th Floor, 3
- Itaewon-ro 55ga-gil
- Seoul, Yongsan 04348
- South Korea
Corporate Office
- 5th Floor, 3
- Itaewon-ro 55ga-gil
- Seoul, Yongsan 04348
- South Korea
Kanaph Therapeutics Timeline
Kanaph Therapeutics Stock Performance
As of 13-Nov-2026, Kanaph Therapeutics’s stock price is $6.67. Its current market cap is $87.3M with 13.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.67 | $6.78 | $5.99 - $37.75 | $87.3M | 13.1M | 84.1K | $0.54 |
Kanaph Therapeutics Financials Summary
As of 30-Sep-2026, Kanaph Therapeutics has a trailing 12-month revenue of $2.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 81,930 | |||
| Revenue | 2,596 | 3,907 | 3,116 | 267 |
| EBITDA | (8,702) | (21,909) | (16,790) | (6,557) |
| Net Income | (8,627) | (24,987) | (20,720) | (9,626) |
| Total Assets | 33,853 | 10,737 | 13,594 | 15,689 |
| Total Debt | 638 | 212 | 332 | 195 |
Kanaph Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kanaph Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kanaph Therapeutics Patents
Kanaph Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026038916-A1 | Novel compound having sos1 inhibitory activity | Pending | 14-Aug-2024 | ||
| AU-2024220775-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Pending | 16-Feb-2023 | ||
| EP-4667464-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Pending | 16-Feb-2023 | ||
| WO-2024172632-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Inactive | 16-Feb-2023 | ||
| JP-2026507483-A | Azolylpyridine pyridazinone amides as sos1 inhibitors | Pending | 16-Feb-2023 | C07D401/14 |
Kanaph Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kanaph Therapeutics FAQs
-
When was Kanaph Therapeutics founded?
Kanaph Therapeutics was founded in 2019.
-
Where is Kanaph Therapeutics headquartered?
Kanaph Therapeutics is headquartered in Seoul, South Korea.
-
What is the size of Kanaph Therapeutics?
Kanaph Therapeutics has 30 total employees.
-
What industry is Kanaph Therapeutics in?
Kanaph Therapeutics’s primary industry is Drug Discovery.
-
Is Kanaph Therapeutics a private or public company?
Kanaph Therapeutics is a Public company.
-
What is Kanaph Therapeutics’s stock symbol?
The ticker symbol for Kanaph Therapeutics is 0082N0.
-
What is the current stock price of Kanaph Therapeutics?
As of 13-Nov-2026 the stock price of Kanaph Therapeutics is $6.67.
-
What is the current market cap of Kanaph Therapeutics?
The current market capitalization of Kanaph Therapeutics is $87.3M.
-
What is Kanaph Therapeutics’s current revenue?
The trailing twelve month revenue for Kanaph Therapeutics is $2.6M.
-
What is Kanaph Therapeutics’s annual earnings per share (EPS)?
Kanaph Therapeutics’s EPS for 12 months was $0.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
